Colorectal Cancer

KRAS-Mutated Metastatic CRC

A small subset of patients with colorectal cancer benefited from the combination of nivolumab (Opdivo) and pixatimod (PG545), according to early results from a phase Ib trial.

Pashtoon M. Kasi, MD, MBBS, MS,&nbsp;provides an overview of the potential for liquid biopsies in CRC and advances being made in the treatment landscape. &nbsp;<br /> &nbsp;

Raymond Wadlow, MD, discusses the results for the randomized phase II CCTG CO.26 trial investigating the use of immunotherapy versus best supportive care in heavily pretreated patients with colorectal cancer.

Axel Grothey, MD,&nbsp;discussed the results from a safety lead-in cohort to the BEACON CRC trial and highlighted the significance of these data.

General Cancer

Axel Grothey, MD, discusses the results from the safety lead-in phase of the BEACON CRC trial investigating the triplet regimen of BRAF inhibitor encorafenib, MEK inhibitor binimetinib, and anti-EGFR antibody cetuximab in&nbsp;patients with&nbsp;<em>BRAF</em>V600E-mutant metastatic colorectal cancer.

A&nbsp;direct-to-consumer genetic test has been approved by the FDA for providing a&nbsp;risk report on MUTYH-associated polyposis, a hereditary colorectal cancer syndrome, according to&nbsp;23andMe, the personal genetics company that manufactures the test.<br /> &nbsp;

Michael J. Overman, MD, discusses the data presented at the 2019 Gastrointestinal Cancers Symposium for the phase II CheckMate-142 in previously treated patients with microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer.

Treatment with&nbsp;durvalumab demonstrated&nbsp;objective responses in approximately one-fourth of patients with&nbsp;microsatellite instability-high advanced solid tumors, including colorectal cancer, according to data from 2 preliminary clinical trials.